Astria Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Astria Therapeutics, Inc.
Finance Watch: Public Biopharma Firms Take Advantage Of Relative Upswing
Public Company Edition: Prometheus brought in $500m from a follow-on offering after reporting positive mid-stage results for its TL1A inhibitor. Even Novavax, struggling to make money from its COVID-19 vaccine, raised cash in dual offerings, but its valuation dropped significantly afterward.
Perceptive And Xontogeny’s Second VC Fund Brings In $515m
The strategy for both funds is to back companies with a preclinical drug candidate that can be advanced through clinical proof-of-concept with a mid-sized series A round.
Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Catabasis’s Future In Doubt After DMD Phase III Failure
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
- Large Molecule
- Other Names / Subsidiaries
- Catabasis Pharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.